Former Novartis and Merck ace is Kymab’s first CMO
Anbtibodies powerhouse Kymab has appointed immunologist Dr Sonia Quaratino as its first chief medical officer. Dr Quaratino (pictured) will manage the clinical development of the group’s expanding therapeutic antibody portfolio.
She joins Kymab from Novartis, where she has served as global clinical programme leader for transitional clinical oncology, responsible for the clinical development of proprietary therapeutic antibody programmes in immuno-oncology.
Prior to her role with Novartis, Dr Quaratino was senior medical director and immunology adviser at Merck Serono, where she was responsible for the clinical development of various immunomodulators.
Dr Quaratino also has more than 20 years of professional experience in biomedical research in UK academic institutions including Imperial College London and the University of Southampton.
Kymab CEO Dr David Chiswell said: “With her demonstrated track record in clinical development and medical affairs, Sonia is a superb addition to Kymab‘s management team as we prepare for our first clinical trials. Sonia’s deep understanding of the global environment in clinical research complement those of Dr Arndt Schottelius, our new Executive VP of R&D who recently joined us from Morphosys.
“These two key appointments add a high calibre of depth and provide further validation to our burgeoning and advancing R & D pipeline.”
Dr Quaratino added: “Kymab’s emerging human antibody pipeline provides great potential to improve patient treatment options in our four main therapeutic areas of focus: immuno-oncology; auto-immunity; haematology and infectious disease.
“The Kymouse technology that underpins the company contains a full set of human immunoglobulin light and heavy chain genes that can produce 10 trillion different antibodies, thus significantly increasing the chances of finding new best-in-class antibodies.”
Dr Quaratino has an extensive professional background which includes a medical degree and a doctorate in haematology-oncology from the University of Palermo, Italy and a Ph.D. in immunology from Imperial College London.